Emergent BioSolutions (EBS) Stock Research, Analysis & News

Quick Analysis on Emergent BioSolutions (EBS) Stock as of April 21, 2019

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Emergent BioSolutions (EBS) Stock below)

Emergent BioSolutions (EBS) Stock Profile Summary

Emergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. It is also developing BioThrax related programs to enhance BioThrax as a medical countermeasure for use as a post-exposure prophylaxis against anthrax disease; BioThrax dual adjuvant vaccine to provide rapid immunity; rPA vaccine and Double-mutant rPA vaccines for anthrax; Anthrax immune globulin therapeutic, a therapeutic antibody product candidate for the treatment of symptomatic anthrax disease; and Anthrax monoclonal antibody therapeutic, a human monoclonal antibody product candidate for treatment of patients who present symptoms of anthrax disease. The companys other product candidates in the development comprise tuberculosis vaccine, a single-dose injectable vaccine for use in persons who have been vaccinated with Bacille Calmette-Guerin; Typhella, a single-dose drinkable vaccine for typhoid; a vaccine for the prevention of influenza strains across multiple seasons; and a vaccine to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions was founded in 1998 and is based in Rockville, Maryland.

Emergent BioSolutions (EBS) Stock Key Statistics Research and Analysis as of April 21, 2019

Emergent BioSolutions (EBS) Stock Competitor Research and Analysis

Crucell NV (CRXL)Human Genome Sciences Inc. (HGSI)
Amgen Inc. (AMGN)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)
Bristol-Myers Squibb Company (BMY)

Mutual Funds with Emergent BioSolutions (EBS) Stock in its top 10 holdings

FundCategoryEBS Holding Percentage
Aberdeen Small Cap RSmall Growth2.7%
Glenmede US Emerging GrowthSmall Growth1.47%
Loomis Sayles Small Cap Growth RetailSmall Growth1.57%
Nuveen Symphony Small Cap Core ASmall Blend1.62%
Putnam Capital Opportunities ASmall Blend2.06%

ETFs with Emergent BioSolutions (EBS) Stock in its top 10 holdings

Stock Research on Emergent BioSolutions (EBS)

Latest Market News on Emergent BioSolutions (EBS)


Click here to find the latest news on Emergent BioSolutions (EBS)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Crucell NV (CRXL)
Human Genome Sciences Inc. (HGSI)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)
Bristol-Myers Squibb Company (BMY)